ReviewKidney3602020
Gadolinium-Based Contrast Agent Use, Their Safety, and Practice Evolution.
Review in Kidney360, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 121 citations in OpenAlex.
- Gadolinium-Based Contrast Agents and the Theater of Safety.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Response to Dr. Do.Magnetic resonance imaging · 2026Article
- Synthesis and Characterization of a Novel Biphenol-Based Gadolinium Complex for Encapsulation in Human Red Blood Cells.International journal of molecular sciences · 2026Article
- Magnetic nanoparticle contrast agents for MRI: structure-property relationships,Nanotechnology · 2026Review
- Gadolinium Pollution-A Future Forward Perspective on Human and Environmental Impact.Magnetic resonance in medicine · 2026Review
- Challenges in Controlled Doping of NaMnFACS omega · 2026Article
- In vitro Effects of Gadoteric Acid and Iobitridol Toxicity and Platelet-Rich Plasma-Mediated Protection in Human Annulus Fibrosus and Nucleus Pulposus Cells.Journal of pain research · 2026Article
- Gadolinium Intermediate Elimination and Persistent Symptoms After Magnetic Resonance Imaging Contrast Agent Exposure.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2025Article
- Advanced Neuroimaging and Emerging Systemic Therapies in Glioblastoma: Current Evidence and Future Directions.Biomedicines · 2025Review
- Simultaneous TMagnetic resonance in medicine · 2025Article
- Evaluating the use of lanthanide containing dendrimers for solvent paramagnetic relaxation enhancement.Journal of biomolecular NMR · 2025Article
- Direct shoulder MR arthrography using an iron-based positive T1 contrast agent (NEMO-103): comparison of image quality with gadolinium-based contrast.Scientific reports · 2025Article
- Precipitation of gadolinium from magnetic resonance imaging contrast agents may be the Brass tacks of toxicity.Magnetic resonance imaging · 2025Article
- Gadolinium-Based Contrast Agents (GBCAs) for MRI: A Benefit-Risk Balance Analysis from a Chemical, Biomedical, and Environmental Point of View.Global challenges (Hoboken, NJ) · 2025Review
- The Role of Synthetic MRI and Radiomics in Breast Cancer: A Review.Advanced biomedical research · 2025Review
- Iron(III)-Quercetin Complex: In Vivo Acute Toxicity and Biodistribution of Novel MRI Agent.International journal of nanomedicine · 2025Article
- Composite Contrast Enhancement of Hydrogel-Based Implants for Photon-Counting Computed Tomography Studies.Gels (Basel, Switzerland) · 2024Article
- Application of rare earth elements in dual-modality molecular probes.RSC advances · 2024Review
- Contribution of Magnetic Resonance Imaging Studies to the Understanding of Cerebral Malaria Pathogenesis.Pathogens (Basel, Switzerland) · 2024Review
- Diagnostic CT cystography with diluted gadolinium-based contrast: A viable alternative to an iodinated contrast-based cystogram.Urology case reports · 2024Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Gadolinium-based contrast agents (GBCAs) have provided much needed image enhancement in magnetic resonance imaging (MRI) important in the advancement of disease diagnosis and treatment. The paramagnetic properties of ionized gadolinium have facilitated these advancements, but ionized gadolinium carries toxicity risk. GBCAs were formulated with organic chelates designed to reduce these toxicity risks from unbound gadolinium ions. They were preferred over iodinated contrast used in computed tomography and considered safe for use. As their use expanded, the development of new diseases associated with their use (including nephrogenic systemic fibrosis) has drawn more attention and ultimately caution with their clinical administration in those with impaired renal function. Use of GBCAs in those with preserved renal function was considered to be safe. However, in this new era with emerging clinical and experimental evidence of brain gadolinium deposition in those with repeated exposure, these safety assumptions are once again brought into question. This review article aims to add new perspectives in thinking about the role of GBCA in current clinical use. The new information begs for further discussion and consideration of the risk-benefit ratio of use of GBCAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.